1895MO Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy with poor prognosis.In Japan, nivolumab was approved in August 2018 for patients with pemetrexed-platinum doublet-treated MPM based on the MERIT trial results.Here, we report the 3-year follow-up data of the MERIT trial to update the previous report. Enrollment criteria were as follows: Japanese patients with advanced or metastatic MPM previously treated with up to...